skip to Main Content

PERSONALIZED WOUND HEALING

Diabetic foot ulcers have a debilitating impact on patients. Despite numerous treatment options, about 60% of all patients experience a wound that does not heal.2 If the severity of a wound progresses to grade 4 or 5, the cost of treatment is eight times higher than a grade 1 or 2 wound.3 For about 20% of patients, treatment ends in amputation within one year.4

At Reapplix, we have established that one of the keys to successful wound treatment lies in the body’s capacity to heal – and each patient is central to that process. Using just a small sample of the patient’s blood – nothing else – the 3C Patch® System separates, coagulates and compacts the blood components into a solid patch. The result is a single 3C Patch® comprising a concentration of proteins, active cells and growth factors.

Each 3C Patch® takes about 20 minutes to produce and is applied directly to the wound at point-of-care. One of few evidence-based wound treatments, the 3C Patch® is clinically proven to significantly accelerate wound healing of hard-to-heal diabetic foot ulcers.1 The outcome is a cost-effective, personalized wound treatment that draws on each patient’s unique ability to help their own healing process.

Every wound is personal.

 

About Reapplix

Learn more about the company

About 3C Patch®

Learn more about the product

Reapplix 3C Patch® therapy recommended for enhancement of healing diabetic foot ulcers by international working group on the diabetic foot (IWGDF)

The International Working Group on the Diabetic Foot (IWGDF) now recommends the use of Reapplix’s technology, the 3C Patch®, an autologous combined leucocyte, platelet and fibrin, as an adjunctive treatment. Press release

Read the full guideline here

New Publication in The Lancet Diabetes & Endocrinology

The positive outcome data of an independent Randomized Controlled Trial (RCT) of 3C Patch® was published in The Lancet Diabetes & Endocrinolocy on September 19, 2018.1 The results have also been presented at many scientific meetings in USA and Europe including the American Diabetes Association 78th Scientific Sessions meeting, June 2018, the Diabetic Foot Study Group Conference September 2018, and at the annual meeting of the European Association for the Study of Diabetes (EASD), October 2018.

The Lancet Publication

REFERENCES

1. Game F., Jeffcoate W., Tarnow L., Jacobsen JL., Whitham DJ., Harrison EF., Ellender SJ., Fitzsimmons D., Löndahl M., LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden:an observer-masked randomized controlled trial. www.thelancet.com/diabetes-endocrinology. Published online September 19, 2018. The Lancet publication

2. Stadler L, Wound Debridement – Robust Growth in a Dynamic Market, SmartTRAK 2018

3. Stevens P, The Cost of Diabetic Foot Ulcers, The O&P Edge, August 2015, seen 19 March 2019

4. Prompers L et al, Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease, Diabetologia, 2008; 51(5): 747–755

Back To Top
X